Skip to main content

Hormonal Therapy after Pertuzumab and Trastuzumab for the Treatment of Hormone Receptor Positive, HER2 Positive Breast Cancer, the ADEPT study

Trial Status: Active

This phase II trial studies the effect of hormonal therapy given after (adjuvant) pertuzumab and trastuzumab in treating patients with hormone receptor positive, HER2 positive breast cancer. The drugs trastuzumab and pertuzumab are both monoclonal antibodies, which are disease-fighting proteins made by cloned immune cells. Estrogen can cause the growth of breast cancer cells. Hormonal therapy, such as letrozole, anastrozole, exemestane, and tamoxifen, block the use of estrogen by the tumor cells. Giving hormonal therapy after pertuzumab and trastuzumab may kill any remaining tumor cells in patients with breast cancer.

Inclusion Criteria

  • HER2-positive T1 histologically confirmed invasive carcinoma of the breast. Patients must have node-negative (N0) or micrometastases (N1mi) breast cancer according to the American Joint Committee on Cancer (AJCC) 8th edition anatomic staging table * If the patient has had a negative sentinel node biopsy, then no further axillary dissection is required, and the patient is determined to be node-negative. Axillary nodes with single cells or tumor clusters =< 0.2 mm by either hematoxylin and eosin (H&E) or immunohistochemistry (IHC) will be considered node-negative * Any axillary lymph node with tumor clusters between 0.02 and 0.2 cm is considered a micrometastasis. Patients with a micrometastasis are eligible. An axillary dissection is not required to be performed in patients with a micrometastasis found by sentinel node evaluation. In cases where the specific pathologic size of lymph node involvement is subject to interpretation, the overall principal investigator will make the final determination as to eligibility. The investigator must document approval in the patient medical record * Patients who have an area of T1aN0, estrogen receptor (ER)+ (defined as >= 10%), HER2-negative cancer in either breast, in addition to their primary HER2 positive tumor, are eligible
  • For unifocal disease, all invasive disease must have been tested for ER and progesterone receptor (PR) (for multifocal disease, see below). Either ER or PR must be positive, defined as ER >= 10% or PR >= 10%. ER- and PR-assays should be performed by immunohistochemical methods according to the local institution standard protocol
  • HER2-positive by American Society of Clinical Oncology (ASCO) College of American Pathologists (CAP) 2018 guidelines, confirmed by central testing * NOTE: Ductal carcinoma in situ (DCIS) components will not be counted in the determination of HER2 status * NOTE: HER-2 status must be confirmed to be positive by central review prior to patient starting protocol therapy. Patients previously having had HER2 testing by NeoGenomics do not need to undergo retesting for central confirmation of HER2 status. A pathology report documenting testing by NeoGenomics should be provided at time of patient registration
  • Bilateral breast cancers that individually meet eligibility criteria are allowed
  • Patients with multifocal or multicentric disease are eligible as long as each tumor individually meets eligibility criteria, with the following exceptions: (1) central confirmation of HER2 status is needed only for any site of disease that is tested to be HER2-positive by local testing (unless original testing was done by NeoGenomics); (2) all areas that were locally tested for ER and PR status must be ER/PR positive (as defined above)
  • Patients with a history of ipsilateral DCIS are eligible as long as the patient has not received prior hormonal therapy. Patients with a history of contralateral DCIS are not eligible
  • =< 90 days between the date of protocol registration and the patient’s most recent breast surgery for this breast cancer
  • Patients must have undergone definitive breast surgery for the current malignancy. All tumor should be removed by either a modified radical mastectomy or a segmental mastectomy (lumpectomy), with either a sentinel node biopsy or axillary dissection * All margins should be clear of invasive cancer or DCIS (i.e. no tumor on ink). The local pathologist must document negative margins of resection in the pathology report. If all other margins are clear, a positive posterior (deep) margin is permitted, provided the surgeon documents that the excision was performed down to the pectoral fascia and all tumor has been removed. Likewise, if all other margins are clear, a positive anterior (superficial; abutting skin) margin is permitted provided the surgeon documents that all tumor has been removed. Radiation therapy to the conserved breast is required
  • May have received up to 8 weeks of hormonal therapy as adjuvant treatment for this cancer. Patients should otherwise not have received prior hormonal therapy
  • Prior oophorectomy (including for cancer therapy) is allowed
  • Patients undergoing breast conservation therapy (i.e. lumpectomy) must not have any contraindications to radiation therapy
  • Patients who have participated in a window study (treatment with an investigational agent prior to surgery for =< 2 weeks) are eligible. Patients must have discontinued the investigational agent at least 14 days before participation
  • Any menopausal status >= 18 years of age
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • Absolute neutrophil count (ANC) >= 1000/mm^3
  • Hemoglobin >= 8 g/dl
  • Platelets >= 75,000/mm^3
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) both =< 5 x institutional upper limit of normal (ULN)
  • Total bilirubin =< 1.5 mg/dL. For patients with Gilbert syndrome, the direct bilirubin should be =< institutional ULN
  • Serum creatinine =< 2.0 mg/dL OR calculated glomerular filtration rate (GFR) >= 30 mL/min
  • Left ventricular ejection fraction (LVEF) >= 50%
  • Post-menopausal patients must meet one of the following criteria: * Prior bilateral ovariectomy/oophorectomy * Age >= 60 years * Age < 60 years with intact uterus and amenorrhoeic for >= 12 consecutive months prior to chemotherapy and/or endocrine therapy exposure (medication-induced amenorrhea is not acceptable to meet this criterion) * Age < 60 years hysterectomized and follicle-stimulating hormone (FSH) and plasma estradiol levels in the post-menopausal range according to local policies prior to chemotherapy and/or endocrine therapy exposure
  • Willingness to discontinue contraceptive hormonal therapy, e.g. birth control pills, prior to registration and while on study
  • Premenopausal patients must have a negative serum or urine pregnancy test, including women who have had a tubal ligation and women less than 12 months from their last menstrual period
  • Women of childbearing potential and men with partners of childbearing potential must be willing to use one highly effective form of nonhormonal contraception or two effective forms of nonhormonal contraception by the patient and/or partner and continue its use for the duration of the study treatment and for 7 months after the last dose of antibody treatment and 3 months after the last dose of hormonal treatment
  • Patients must be willing and able to sign informed consent
  • Patients must be willing to provide archival tissue for research purposes
  • If patient is English-speaking, must be willing to fill out patient questionnaires

Exclusion Criteria

  • Neoadjuvant or adjuvant chemotherapy for this breast cancer prior to enrollment is prohibited
  • Any of the following due to teratogenic potential of the study drugs: * Pregnant women * Nursing women * Women of childbearing potential who are unwilling to employ adequate contraception (condoms, diaphragms, intrauterine devices [IUDS], surgical sterilization, abstinence, etc). Hormonal birth control methods are not permitted * Men who are unwilling to employ adequate contraception (condoms, surgical sterilization, abstinence, etc)
  • Participants who are receiving any other investigational agents for treatment of breast cancer, unless specific approval is obtained from the sponsor-investigator
  • Locally advanced tumors at diagnosis, including tumors fixed to the chest wall, peau d’orange, skin ulcerations/nodules, or clinical inflammatory changes (diffuse brawny cutaneous induration with an erysipeloid edge)
  • Patients with a history of previous invasive breast cancer
  • Individuals with a history of a different malignancy are ineligible except for the following circumstances: * Individuals with a history of other malignancies are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy * Individuals with the following cancer are eligible regardless of when they were diagnosed and treated: cervical cancer in situ, and non-melanoma cancer of the skin
  • Intercurrent illness including, but not limited to: ongoing or active, unresolved systemic infection, renal failure requiring dialysis, active cardiac disease, prior myocardial infarction (asymptomatic changes on electrocardiogram [EKG] suggestive of old myocardial infarction [MI] is not an exclusion), history of congestive heart failure (CHF), current use of any therapy specifically for CHF, uncontrolled hypertension, significant psychiatric illness, or other conditions that in the opinion of the investigator limit compliance with study requirements

Connecticut

Stamford
Stamford Hospital
Status: ACTIVE
Contact: K.M. Steve Lo

Massachusetts

Boston
Dana-Farber Cancer Institute
Status: ACTIVE
Contact: Adrienne Gropper Waks
Phone: 617-632-3800
Milford
Dana-Farber / Brigham and Women's Cancer Center at Milford Regional
Status: ACTIVE
Contact: Natalie Sinclair
South Weymouth
Dana-Farber / Brigham and Women's Cancer Center at South Shore
Status: ACTIVE
Contact: Meredith Faggen

PRIMARY OBJECTIVE:

I. To evaluate 3-year invasive disease-free survival (iDFS) in patients with stage I hormone receptor positive (HR+) HER2+ breast cancer treated with adjuvant trastuzumab/hyaluronidase-oysk (trastuzumab) and pertuzumab (HP) plus endocrine therapy.

SECONDARY OBJECTIVES:

I. To evaluate iDFS at 7 and 10 years in patients with stage I HR+ HER2+ breast cancer treated with adjuvant HP plus endocrine therapy, in:

Ia. All patients.

Ib. Patient subgroups according to intrinsic subtype (HER2-enriched, luminal, basal).

II. To evaluate recurrence-free interval (RFI) at 3, 7, and 10 years in patients with stage I HR+ HER2+ breast cancer treated with adjuvant HP plus endocrine therapy, in:

IIa. All patients.

IIb. Patient subgroups according to intrinsic subtype (HER2-enriched, luminal, basal).

III. To evaluate breast cancer-specific survival (BCSS) at 3, 7, and 10 years in patients with stage I HR+ HER2+ breast cancer treated with adjuvant HP plus endocrine therapy, in:

IIIa. All patients.

IIIb. Patient subgroups according to intrinsic subtype (HER2-enriched, luminal, basal).

IV. To assess safety and tolerability of one year of subcutaneous HP plus endocrine therapy.

EXPLORATORY AND CORRELATIVE OBJECTIVES:

I. To evaluate quality of life, patient satisfaction, financial concerns, patient acceptance of subcutaneous administration at home, and hormonal therapy adherence over time in patients treated with HP plus endocrine therapy.

II. To explore how the presence, absence, and characteristics (i.e. presence of certain mutations) of detectable circulating tumor deoxyribonucleic acid (DNA) correlates with long-term outcomes (iDFS, RFI, overall survival [OS]) on HP plus hormonal therapy.

III. To explore how features of the pre-treatment immune microenvironment correlate with long-term outcomes (iDFS, RFI, OS) on HP plus hormonal therapy.

OUTLINE:

Patients receive trastuzumab subcutaneously (SC) over 5-8 minutes or intravenously (IV) and pertuzumab SC over 5-8 minutes or IV on day 1. Treatment repeats every 21 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity. Postmenopausal women also receive either letrozole orally (PO) once daily (QD), anastrozole PO QD, or exemestane PO QD, and pre- and postmenopausal women and men receive tamoxifen PO QD on days 1-21. Treatment repeats every 21 days for at least 5 years in the absence of disease progression or unacceptable toxicity. Premenopausal or male patients may receive gonadotropin-releasing hormone analog intramuscularly (IM) once monthly or every 3 months for at least 5 years in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up annually until 10 years after trial registration.

Trial Phase Phase II

Trial Type Treatment

Lead Organization
Dana-Farber Harvard Cancer Center

Principal Investigator
Adrienne Gropper Waks

  • Primary ID 20-347
  • Secondary IDs NCI-2020-13971
  • Clinicaltrials.gov ID NCT04569747